These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24762964)

  • 1. Integrated computational tools for identification of CCR5 antagonists as potential HIV-1 entry inhibitors: homology modeling, virtual screening, molecular dynamics simulations and 3D QSAR analysis.
    Moonsamy S; Dash RC; Soliman ME
    Molecules; 2014 Apr; 19(4):5243-65. PubMed ID: 24762964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based identification of novel scaffolds as potential HIV-1 entry inhibitors involving CCR5.
    Appiah-Kubi P; Iwuchukwu EA; Soliman MES
    J Biomol Struct Dyn; 2022; 40(23):13115-13126. PubMed ID: 34569417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.
    Tan Q; Zhu Y; Li J; Chen Z; Han GW; Kufareva I; Li T; Ma L; Fenalti G; Li J; Zhang W; Xie X; Yang H; Jiang H; Cherezov V; Liu H; Stevens RC; Zhao Q; Wu B
    Science; 2013 Sep; 341(6152):1387-90. PubMed ID: 24030490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational modeling of human coreceptor CCR5 antagonist as a HIV-1 entry inhibitor: using an integrated homology modeling, docking, and membrane molecular dynamics simulation analysis approach.
    Gadhe CG; Kothandan G; Cho SJ
    J Biomol Struct Dyn; 2013; 31(11):1251-76. PubMed ID: 23153179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational Screening of CCR5 Inhibitors as Potential Entry Inhibitor Microbicides Using 3D-QSAR Studies, Docking and Molecular Dynamics Simulation.
    Ramachandran R; Aathi M; Ruban DD; Piramanyagam S
    Curr HIV Res; 2017; 15(4):234-244. PubMed ID: 28059045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hybrid Virtual Screening Approach to Predict Novel Natural Compounds against HIV-1 CCR5.
    Eid AM; Selim A; Khaled M; Elfiky AA
    J Phys Chem B; 2024 Jul; 128(29):7086-7101. PubMed ID: 39016126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potential CCR5 inhibitors through pharmacophore-based virtual screening, molecular dynamics simulation and binding free energy analysis.
    Wang J; Shu M; Wang Y; Hu Y; Wang Y; Luo Y; Lin Z
    Mol Biosyst; 2016 Oct; 12(11):3396-3406. PubMed ID: 27714030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophore-Oriented Identification of Potential Leads as CCR5 Inhibitors to Block HIV Cellular Entry.
    Singh P; Kumar V; Lee G; Jung TS; Ha MW; Hong JC; Lee KW
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
    Zheng Y; Han GW; Abagyan R; Wu B; Stevens RC; Cherezov V; Kufareva I; Handel TM
    Immunity; 2017 Jun; 46(6):1005-1017.e5. PubMed ID: 28636951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).
    Garcia-Perez J; Rueda P; Alcami J; Rognan D; Arenzana-Seisdedos F; Lagane B; Kellenberger E
    J Biol Chem; 2011 Sep; 286(38):33409-21. PubMed ID: 21775441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
    Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop.
    Tamamis P; Floudas CA
    PLoS One; 2014; 9(4):e95767. PubMed ID: 24763408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.
    El-Hage N; Dever SM; Podhaizer EM; Arnatt CK; Zhang Y; Hauser KF
    AIDS; 2013 Sep; 27(14):2181-90. PubMed ID: 23751259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational study on the interaction between CCR5 and HIV-1 entry inhibitor maraviroc: insight from accelerated molecular dynamics simulation and free energy calculation.
    Bai Q; Zhang Y; Li X; Chen W; Liu H; Yao X
    Phys Chem Chem Phys; 2014 Nov; 16(44):24332-8. PubMed ID: 25296959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural biology. A new bundle of prospects for blocking HIV-1 entry.
    Klasse PJ
    Science; 2013 Sep; 341(6152):1347-8. PubMed ID: 24030494
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
    Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
    Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constructing an atomic-resolution model of human P2X7 receptor followed by pharmacophore modeling to identify potential inhibitors.
    Ahmadi M; Nowroozi A; Shahlaei M
    J Mol Graph Model; 2015 Sep; 61():243-61. PubMed ID: 26298810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics, interactions and mechanism of action of maraviroc].
    Soriano V; Poveda E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():12-6. PubMed ID: 19133216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.